Chemed Management
Management Kriterienprüfungen 3/4
Chemed CEO ist Kevin McNamara , ernannt in Aug 1994, hat eine Amtszeit von 31.92 Jahren. Die jährliche Gesamtvergütung beträgt $12.90M , bestehend aus 14.4% Gehalt und 85.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.68% der Aktien des Unternehmens, im Wert von $46.34M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 26.2 Jahre bzw. 17.7 Jahre.
Wichtige Informationen
Kevin McNamara
Geschäftsführender
US$12.9m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 14.40% |
| Amtszeit als Geschäftsführer | 31.9yrs |
| Eigentum des Geschäftsführers | 0.7% |
| Durchschnittliche Amtszeit des Managements | 26.2yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 17.7yrs |
Jüngste Management Updates
Recent updates
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy
Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking AlphaNew Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$260m |
| Dec 31 2025 | US$13m | US$2m | US$265m |
| Sep 30 2025 | n/a | n/a | US$279m |
| Jun 30 2025 | n/a | n/a | US$290m |
| Mar 31 2025 | n/a | n/a | US$309m |
| Dec 31 2024 | US$13m | US$2m | US$302m |
| Sep 30 2024 | n/a | n/a | US$302m |
| Jun 30 2024 | n/a | n/a | US$301m |
| Mar 31 2024 | n/a | n/a | US$283m |
| Dec 31 2023 | US$13m | US$2m | US$273m |
| Sep 30 2023 | n/a | n/a | US$245m |
| Jun 30 2023 | n/a | n/a | US$226m |
| Mar 31 2023 | n/a | n/a | US$240m |
| Dec 31 2022 | US$12m | US$1m | US$250m |
| Sep 30 2022 | n/a | n/a | US$262m |
| Jun 30 2022 | n/a | n/a | US$277m |
| Mar 31 2022 | n/a | n/a | US$267m |
| Dec 31 2021 | US$12m | US$1m | US$269m |
| Sep 30 2021 | n/a | n/a | US$308m |
| Jun 30 2021 | n/a | n/a | US$303m |
| Mar 31 2021 | n/a | n/a | US$329m |
| Dec 31 2020 | US$12m | US$1m | US$319m |
| Sep 30 2020 | n/a | n/a | US$271m |
| Jun 30 2020 | n/a | n/a | US$263m |
| Mar 31 2020 | n/a | n/a | US$231m |
| Dec 31 2019 | US$10m | US$1m | US$220m |
Vergütung im Vergleich zum Markt: KevinDie Gesamtvergütung ($USD12.90M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD8.31M).
Entschädigung vs. Einkommen: KevinDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Kevin McNamara (72 yo)
Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corporation since May 2001 and President since August 2, 1994. Mr. McNamara served as an Executive Vice President and Secretary of Cheme...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 31.9yrs | US$12.90m | 0.68% $ 46.3m | |
| Executive VP | 14.2yrs | US$3.71m | 0.045% $ 3.1m | |
| VP, Secretary & Chief Legal Officer | 5.9yrs | US$2.66m | 0.018% $ 1.3m | |
| Executive Vice President | 26.2yrs | US$3.21m | 0.11% $ 7.7m | |
| VP & Director | 38.4yrs | keine Daten | 0.60% $ 41.1m | |
| Executive VP and President & CEO of VITAS Healthcare | 2.5yrs | US$3.05m | 0.0065% $ 438.0k | |
| VP, Chief Administrative Officer & Assistant Secretary | 31.7yrs | keine Daten | keine Daten | |
| Director of Investor Relations | no data | keine Daten | keine Daten | |
| VP & Chief Strategy Officer | no data | keine Daten | keine Daten | |
| Vice President & Assistant Controller | no data | keine Daten | keine Daten |
Erfahrenes Management: Das Managementteam von CHE ist erfahren und erfahren (durchschnittliche Amtszeit von 26.2 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 39.5yrs | US$12.90m | 0.68% $ 46.3m | |
| VP & Director | 41.5yrs | keine Daten | 0.60% $ 41.1m | |
| Director Emeritus | 17.2yrs | US$157.02k | keine Daten | |
| Independent Director | 30.5yrs | US$313.89k | 0.028% $ 1.9m | |
| Independent Chairman | 31.5yrs | US$495.03k | 0.028% $ 1.9m | |
| Independent Director | 18.2yrs | US$275.39k | 0.035% $ 2.4m | |
| Independent Director | 3.2yrs | US$275.39k | 0.0094% $ 637.6k | |
| Independent Director | 6.2yrs | US$286.39k | 0.021% $ 1.4m | |
| Independent Director | 6.2yrs | US$281.89k | 0.016% $ 1.1m | |
| Independent Director | 3.9yrs | US$281.89k | 0.010% $ 676.3k |
Erfahrener Vorstand: CHEDie Vorstandsmitglieder sind sehr erfahren ( 17.7 ).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/21 13:03 |
| Aktienkurs zum Tagesende | 2026/07/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Chemed Corporation wird von 10 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |